Abiopharma

🔍 MANCHESTER MANAGEMENT CO LLC (Executive)

Company: SANUWAVE Health, Inc. (SNWV)

Report Date: 2025-12-11

Detailed Transactions and Holdings:

• Sold 13,500 shares of Common Stock, par value $0.001 at $31.2798 per share (Direct)
  Date: 2025-12-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 70,499.00 | transaction_form_type: 4 | Footnotes: F2, F1
• Sold 6,500 shares of Common Stock, par value $0.001 at $21.0444 per share (Direct)
  Date: 2025-12-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 63,999.00 | transaction_form_type: 4 | Footnotes: F3, F1
• Holds 0 shares of Common Stock, par value $0.001 (Direct)
  Date: 2025-12-11 | Code: H | shares_owned_after: 2,000.00 | Footnotes: F4
• Holds 0 shares of Common Stock, par value $0.001 (Direct)
  Date: 2025-12-11 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 863,980.00 | Footnotes: F5
• Holds 0 shares of Common Stock, par value $0.001 (Direct)
  Date: 2025-12-11 | Code: H | shares_owned_after: 52,653.00 | Footnotes: F6

Footnotes:

• F1: The reported securities are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Manchester Explorer, L.P. ("Explorer"), (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $31.05 to $31.525. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $30.765 to $31.60. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: The reported securities are directly owned by James E. Besser in his personal capacity.
• F5: The reported securities are owned directly by Explorer and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of Explorer, (ii) Manchester PR, the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
• F6: The reported securities and warrants are directly owned by Morgan C. Frank in his personal capacity.